TTR and cerebrovascular disorder: Using data from Danish cohort studies, it was determined that patients who are heterozygous for the stabilizing p.T139M TTR variant have increased TTR levels and decreased risks of cerebrovascular disease and all-cause death [49,54]; however, these data were not reproduced in the UK Biobank, in which p.T139M was not associated with protection against cerebrovascular disease or death [134].